Literature DB >> 19624539

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.

John Gerecitano1, Carol Portlock, Craig Moskowitz, Paul Hamlin, David Straus, Andrew D Zelenetz, Zhigang Zhang, Otilia Dumitrescu, Debra Sarasohn, Dorothy Lin, Jennifer Pappanicholaou, Barbara M Cortelli, Ellen Neylon, Rachel Hamelers, John Wright, Owen A O'Connor.   

Abstract

Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, P = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19624539      PMCID： PMC4035037          DOI： 10.1111/j.1365-2141.2009.07775.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  12 in total

1.  A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.

Authors:  A Belch; C T Kouroukis; M Crump; L Sehn; R D Gascoyne; R Klasa; J Powers; J Wright; E A Eisenhauer
Journal:  Ann Oncol       Date:  2006-09-13       Impact factor: 32.976

2.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Authors:  Owen A O'Connor; John Wright; Craig Moskowitz; Jamie Muzzy; Barbara MacGregor-Cortelli; Michael Stubblefield; David Straus; Carol Portlock; Paul Hamlin; Elizabeth Choi; Otila Dumetrescu; Dixie Esseltine; Elizabeth Trehu; Julian Adams; David Schenkein; Andrew D Zelenetz
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

3.  Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Authors:  Andre Goy; Anas Younes; Peter McLaughlin; Barbara Pro; Jorge E Romaguera; Frederick Hagemeister; Luis Fayad; Nam H Dang; Felipe Samaniego; Michael Wang; Kristine Broglio; Barry Samuels; Frederic Gilles; Andreas H Sarris; Susan Hart; Elizabeth Trehu; David Schenkein; Fernando Cabanillas; Alma M Rodriguez
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

4.  Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

Authors:  Sandra J Strauss; Lenushka Maharaj; Susan Hoare; Peter W Johnson; John A Radford; Sarah Vinnecombe; Lynda Millard; Ama Rohatiner; Anthony Boral; Elizabeth Trehu; David Schenkein; Frances Balkwill; Simon P Joel; T Andrew Lister
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

5.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Richard I Fisher; Steven H Bernstein; Brad S Kahl; Benjamin Djulbegovic; Michael J Robertson; Sven de Vos; Elliot Epner; Amrita Krishnan; John P Leonard; Sagar Lonial; Edward A Stadtmauer; Owen A O'Connor; Hongliang Shi; Anthony L Boral; André Goy
Journal:  J Clin Oncol       Date:  2006-09-25       Impact factor: 44.544

6.  Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

Authors:  Ulrike Heider; Ivana von Metzler; Martin Kaiser; Marleen Rosche; Jan Sterz; Susanne Rötzer; Jessica Rademacher; Christian Jakob; Claudia Fleissner; Ulrike Kuckelkorn; Peter-Michael Kloetzel; Orhan Sezer
Journal:  Eur J Haematol       Date:  2007-12-20       Impact factor: 2.997

7.  The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Authors:  Luca Paoluzzi; Mithat Gonen; Govind Bhagat; Richard R Furman; Jeffrey R Gardner; Luigi Scotto; Volodia D Gueorguiev; Mark L Heaney; Katia Manova; Owen A O'Connor
Journal:  Blood       Date:  2008-06-30       Impact factor: 22.113

8.  Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.

Authors:  John D Hainsworth; David R Spigel; John Barton; Cindy Farley; Marshall Schreeder; Jeremy Hon; F Anthony Greco
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

9.  Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes.

Authors:  Owen A O'Connor; Carol Portlock; Craig Moskowitz; Paul Hamlin; David Straus; John Gerecitano; Mithat Gonen; Otilia Dumitrescu; Debra Sarasohn; John Butos; Ellen Neylon; Barbara Mac-Gregor Cortelli; Susan Blumel; Andrew M Evens; Andrew D Zelenetz; John Wright; Brenda Cooper; Jane Winter; Julie Vose
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

10.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Authors:  Christos N Papandreou; Danai D Daliani; Darrell Nix; Hong Yang; Timothy Madden; Xuemei Wang; Christine S Pien; Randall E Millikan; Shi-Ming Tu; Lance Pagliaro; Jeri Kim; Julian Adams; Peter Elliott; Dixie Esseltine; Alexandria Petrusich; Pauline Dieringer; Cherie Perez; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544
View more
  19 in total

1.  Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia.

Authors:  Alison R Walker; Rebecca B Klisovic; Ramiro Garzon; Larry J Schaaf; Kristina Humphries; Steven M Devine; John C Byrd; Michael R Grever; Guido Marcucci; William Blum
Journal:  Leuk Lymphoma       Date:  2013-09-09

Review 2.  The future of small molecule inhibitors in lymphoma.

Authors:  John Gerecitano
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075

Review 3.  Bortezomib for the treatment of non-Hodgkin's lymphoma.

Authors:  Prithviraj Bose; Michael S Batalo; Beata Holkova; Steven Grant
Journal:  Expert Opin Pharmacother       Date:  2014-09-29       Impact factor: 3.889

4.  Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.

Authors:  John Gerecitano; Carol Portlock; Paul Hamlin; Craig H Moskowitz; Ariela Noy; David Straus; Philip Schulman; Otilia Dumitrescu; Debra Sarasohn; Jennifer Pappanicholaou; Alexia Iasonos; Zhigang Zhang; Qianxing Mo; Endri Horanlli; Celeste N Rojas; Andrew D Zelenetz; Owen A O'Connor
Journal:  Clin Cancer Res       Date:  2011-02-23       Impact factor: 12.531

5.  The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Authors:  Jonathan W Friedberg; Julie M Vose; Jennifer L Kelly; Faith Young; Steven H Bernstein; Derick Peterson; Lynn Rich; Susan Blumel; Nicole K Proia; Jane Liesveld; Richard I Fisher; James O Armitage; Steven Grant; John P Leonard
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

6.  Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.

Authors:  Alyson J Smith; Haiming Dai; Cristina Correia; Rie Takahashi; Sun-Hee Lee; Ingo Schmitz; Scott H Kaufmann
Journal:  J Biol Chem       Date:  2011-03-22       Impact factor: 5.157

Review 7.  Proteasome inhibitors in cancer therapy.

Authors:  Elisabet E Manasanch; Robert Z Orlowski
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675

8.  Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.

Authors:  Brian G Till; Hongli Li; Steven H Bernstein; Richard I Fisher; W Richard Burack; Lisa M Rimsza; Justin D Floyd; Marco A DaSilva; Dennis F Moore; Olga Pozdnyakova; Sonali M Smith; Michael LeBlanc; Jonathan W Friedberg
Journal:  Br J Haematol       Date:  2015-10-22       Impact factor: 6.998

9.  Novel agents in indolent lymphomas.

Authors:  Michele Merli; Andrea Ferrario; Claudia Basilico; Margherita Maffioli; Domenica Caramazza; Lorena Appio; Luca Arcaini; Francesco Passamonti
Journal:  Ther Adv Hematol       Date:  2013-04

10.  Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.

Authors:  William Blum; Sebastian Schwind; Somayeh S Tarighat; Susan Geyer; Ann-Kathrin Eisfeld; Susan Whitman; Alison Walker; Rebecca Klisovic; John C Byrd; Ramasamy Santhanam; Hongyan Wang; John P Curfman; Steven M Devine; Samson Jacob; Celia Garr; Cheryl Kefauver; Danilo Perrotti; Kenneth K Chan; Clara D Bloomfield; Michael A Caligiuri; Michael R Grever; Ramiro Garzon; Guido Marcucci
Journal:  Blood       Date:  2012-05-07       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.